Automotive and Transportation Automotive and Transportation

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?


Published on 2025-01-02 21:01:07 - MSN
  Print publication without navigation

  • Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes industry. Recently, Tesla (TSLA) CEO Elon Musk added to the buzz by sharing his views on weight-loss-focused pharmaceutical companies.

The article discusses Elon Musk's perspective on the investment potential of two pharmaceutical companies, Eli Lilly (LLY) and Novo Nordisk (NVO), which are both involved in the development and marketing of weight loss drugs. Musk, known for his influence in various industries, commented on the stocks during a recent interview, highlighting the growing market for obesity treatments. He did not explicitly endorse one over the other but pointed out the significant market opportunity due to increasing global obesity rates. The article delves into the specifics of each company's offerings, with Eli Lilly's Mounjaro and Novo Nordisk's Wegovy being highlighted as leading treatments. It also covers the financial performance, market share, and future growth prospects of both companies, noting that while both are strong contenders, they face different challenges and opportunities in the competitive landscape of weight loss pharmaceuticals.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/other/elon-musk-weighs-in-on-weight-loss-drug-stocks-is-lly-or-nvo-a-better-buy/ar-AA1wRDm2 ]